Denosumab Global Market Rising Trends, Industry Size, Share Report, Growing Demand and Business Opportunities And Forecast 2024-2033 | Sanofi SA, GlaxoSmithKline plc, Amgen Inc., Asahi Kasei Corporation, Celltrion Inc.

Spread the love

Overview and Scope
Denosumab is a monoclonal antibody used to treat bone-related conditions, particularly osteoporosis and bone metastases. It works by inhibiting osteoclast formation, decreasing bone resorption, increasing bone mineral density, and reducing the risk of fracture.

Sizing and Forecast
The denosumab market size has grown rapidly in recent years. It will grow from $2.89 billion in 2023 to $3.27 billion in 2024 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to clinical trials and research advancements, FDA approvals and regulatory milestones, growing awareness of bone health, strategic partnerships and marketing initiatives.

The denosumab market size is expected to see rapid growth in the next few years. It will grow to $5.06 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to rising incidence of bone metastases, advancements in cancer therapies, osteoporosis prevalence, increased awareness of osteoporosis, regulatory approvals for new indications. Major trends in the forecast period include strategic collaborations and partnerships, integration with digital health solutions, expanded indications and clinical applications, advancements in biosimilar development.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Segmentation & Regional Insights
The denosumab market covered in this report is segmented –
1) By Drug Classification: Prolia, Xgeva, Others
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

North America was the largest region in the denosumab market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of osteoporosis is expected to propel the growth of the denosumab market going forward. Osteoporosis is a medical condition where the bones become weak, resulting in lower bone density and a higher risk of fractures. Denosumab is used to treat osteoporosis by stopping bone resorption through the targeting of the RANK ligand. For instance, In December 2023, according to a report published by the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, osteoporosis contributed to 2,366 deaths, or 6.5 deaths per 100,000 population in 2021, representing 1.4% of all deaths. Further, in 2021–22, there were 9,500 hospitalizations with a principal diagnosis of osteoporosis (89 hospitalizations per 100,000 population) for people aged 45 and over. Therefore, the increasing prevalence of osteoporosis is driving the growth of the denosumab market.

Key Industry Players
Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

The denosumab market report table of contents includes:
1. Executive Summary